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ABSTRACT 
Objective: The present research was designed to produce methylprednisolone containing chitosan-based nanoparticles using Box-Behnken Design 
(BBD) and Response Surface Methodology (RSM) for optimization.  
Methods: Nanostructures were prepared using the ionic gelation method with screened process parameters. According to the design, 
methylprednisolone chitosan-based nanoparticles (MCSNPs) were optimized using factors like methylprednisolone concentration, stirring speed 
and temperature whereas particle size, zeta potential and % encapsulation efficiency as responses. From the observed values of responses with 
confirmation location and desirability, the predicted values were very close to the observed values.  
Results: Observed values for the optimized formulation have a particle size of 243±2.33 nm with an encapsulation efficiency of 79.3±7.2%. Morphology 
of the particles using scanning electron microscopy reveals nearly spherical shaped particles. Methylprednisolone was released in vitro in a sustained 
manner for about 24 h in simulated colonic fluid pH 7, pH 7.8 (Fasted state) and phosphate buffer pH 7.4, when compared to simulated colonic fluid at 
pH 6 (Fed state). Optimized MCSNPs followed Korsmeyer peppas kinetics with drug release mechanism as anomalous transport. 
Conclusion: Application of Box-Behnken design and Response Surface Methodology using Design Expert software was successfully used in the 
optimization of methylprednisolone loaded chitosan-based nanoparticles with high encapsulation efficiency. 
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INTRODUCTION 
Methylprednisolone is a potent anti-inflammatory agent used in the 
short-term and long-term treatment of Crohn’s disease (CD) [1, 2]. 
Methylprednisolone is BCS class-II drug with the least solubility and high 
permeability with many challenges for the scientists working on novel 
targeted drug delivery system [3]. Methylprednisolone has a maximum 
percentage of remission in CD when compared to ulcerative colitis [4-6]. 
In the present research, methylprednisolone nanoparticles were 
prepared to target the drug into the colon. For this intention, chitosan 
was selected as a polymer because of its biodegradability, 
biocompatibility and ability to sustain the drug release in colonic pH [7]. 
The presence of primary amine at C-2 position of glucosamine residue 
made chitosan as an important polysaccharide for the fabrication of 
functional drug delivery. Ability of chitosan to release the drug in a 
sustained manner is because of the deprotonation of amines that 
undergo inter-polymer associations leading to film and gel formation [8, 
9]. Ionic gelation method was used in the fabrication of MCSNPs due to 
the avoidance of organic solvents with less shear forces [10]. From the 
literature, it was found that methylprednisolone nanoparticles were 
prepared using albumin [11], inulin [12], cyclodextrin polymer [13] etc. 
The present research was accomplished to optimize and 
characterize chitosan-based methylprednisolone nanoparticles 
using Box–Behnken design. The prepared methylprednisolone 
nanoparticles were filled in capsules, which were further coated 
with pH-sensitive polymers like cellulose acetate phthalate and 
eudragit-S 100 using polyethylene glycol-300 as a plasticizer to keep 
chitosan safe in gastric pH. 
MATERIALS AND METHODS 
Materials 
Methylprednisolone was kindly gifted by SP Accure Labs, 
Hyderabad. Chitosan, Tripolyphosphate (TPP) and Phosphatidyl-
choline were purchased from Sigma Aldrich, Mumbai. Eudragit S-
100, Cellulose acetate phthalate was obtained from Drugs India, 
Hyderabad. Tris and Bovine serum albumin from Thermo Fisher 
Scientific, Hyderabad. Sodium phosphate dibasic, Sodium hydroxide, 
Dichloromethane, Potassium phosphate monobasic was obtained 
from New Himalaya Scientific Company, Nellore. All the chemicals 
used were of analytical grade. 
Fabrication of blank chitosan nanoparticles using ionic gelation 
method 
Chitosan (CS) solutions were prepared by dissolving chitosan in aqueous 
acetic acid according to the coded values in table 1 and formulation table 
2. Tripolyphosphate (TPP) aqueous solutions were prepared according 
to the stated quantities and added dropwise to the chitosan solutions 
under stirring at 400 rpm for 100 min using IKA stirrer for preparing 
chitosan nanoparticles (CSNPs). If necessary pH was adjusted to 4.5 
using Mettler Toledo pH meter with 1M aqueous sodium hydroxide 
solution to neutralize the excess acid. Then CS-TPP suspension was 
ultrasonicated using PCI analytics ultrasonicator for 5 min to produce 
CSNPs with controlled sizes. CS-TPP suspension was vacuum filtered 
using Millipore vacuum pump and produced CSNPs were dried. 
The technique was optimized by Design-Expert software using Box-
Behnken design (BBD) with 13 runs, 3-factor, and 3-level as shown in 
table 1. The design is suitable for investigating the quadratic response 
surface and constructing a second-order polynomial model. The 
dependent and independent variables with actual values were shown 
in the table. Temperature (35 °C), pH (4.5) and stirring speed (600 
rpm) was constant variables for preparing chitosan-based 
nanoparticles. 
Fabrication of methylprednisolone loaded chitosan 
nanoparticles using ionic gelation method 
By using the optimized factors of blank CSNPs, formulation 
parameters for preparing methylprednisolone CSNPs were 
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identified and screened through BBD. The dependent and 
independent variables were shown in the table 3. Thirteen batches 
were prepared according to the design as shown in table 4 and 
evaluated for particle size, zeta potential and entrapment efficiency 
(% EE). The concentrations of chitosan, tripolyphosphate and acetic 
acid were kept constant as per the optimized factors of blank CSNPs. 
The method of preparation is the same as the preparation of blank 
CSNPs.
 
Table 1: Variables with coded and actual values for box-behnken design (Formulation–blank CSNPs) 
Independent variables Low Medium High 
Coded values (-1) (0) (-1) 
A = Chitosan (mg/ml) 2 3.5 5 
B =Tripolyphosphate (mg/ml) 0.5 1.25 2 
C = Acetic acid (mg/ml) 0.2 0.5 0.8 
Dependent variables constrains 
Y1 = Particle size (nm): Goal–Minimize 
Y2 = Zeta potential (mV): Goal–In range 
Y3= Poly dispersity Index: Goal–Minimize 
 
Table 2: Formulations showing factors optimized by box-behnken design, (formulation–blank CSNPs) (n=13) 





acetic acid (mg/ml) 
CNI-1 5 1.25 0.8 
CNI-2 2 2 0.5 
CNI-3 3.5 1.25 0.5 
CNI-4 2 1.25 0.2 
CNI-5 2 1.25 0.8 
CNI-6 3.5 2 0.8 
CNI-7 3.5 2 0.2 
CNI-8 5 0.5 0.5 
CNI-9 3.5 0.5 0.8 
CNI-10 3.5 0.5 0.2 
CNI-11 5 2 0.5 
CNI-12 5 1.25 0.2 
CNI-13 2 0.5 0.5 
 
Table 3: Variables with coded and actual values for box-behnken design, (formulation–methylprednisolone CSNPs) 
Independent variables Low Medium High 
Coded Values (-1) (0) (-1) 
A=Methylprednisolone (mg/ml) 0.5 0.75 1 
B=Stirring Speed (rpm) 400 600 800 
C= Temperature ( °C) 10 22.5 35 
Dependent variables Constrains 
Y1 = Particle size (nm): Goal–Minimize 
Y2 = Zeta potential (mV): Goal–Maximize 
Y3= % EE: Goal–Maximize 
 
Table 4: Formulations showing factors optimized by Box-Behnken design, (Formulation–MCSNPs) (n=13) 
Formulation code Factor-1 
methylprednisolone (mg/ml) 
Factor-2 
stirring speed (rpm) 
Factor-3 
temperature ( °C) 
MCSNP-1 1 400 22.5 
MCSNP-2 0.75 600 22.5 
MCSNP-3 1 600 35 
MCSNP-4 0.5 600 35 
MCSNP-5 0.75 400 35 
MCSNP-6 0.5 600 10 
MCSNP-7 1 800 22.5 
MCSNP-8 1 600 10 
MCSNP-9 0.5 400 22.5 
MCSNP-10 0.75 800 35 
MCSNP-11 0.5 800 22.5 
MCSNP-12 0.75 400 10 
MCSNP-13 0.75 800 10 
 
Morphology of CSNPs and MCSNPs 
Morphology and shape analysis of optimized MCSNPs were 
evaluated using SEM (Hitachi S-4300 Microscope). The formulations 
were placed on the double-sided adhesive carbon tabs and adhered 
to aluminium stubs coated with gold/palladium alloy using Emscope 
sputter coating system at 20µA for 1 minute under argon gas. 
Electronic beam at an accelerating voltage of 5-10kV was used at a 
working distance of 13-15 mm. Using similar conditions images 
were captured at several magnifications [14]. 
Particle size and (polydispersity index) PDI 
Freshly prepared nanoparticles of methylprednisolone were diluted 
200 times with deionized water and measured the particle size, PDI 
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and zeta potential using Malvern zeta sizer nano (ZS90). Average 
particle size was measured by dynamic light scattering at an angle of 
90 °. The properties of dispersion and stability of nanoparticles were 
also measured using the same instrument. All the measurements 
were done in a triplicate at 25 °C [15-18]. 
Entrapment efficiency (%EE) 
Amount of methylprednisolone encapsulated in the nanoparticles 
was determined by separating the free drug using 
ultracentrifugation (Remi centrifuge). The formulations were 
centrifuged at around 18,000 rpm for 40 min. The supernatant was 
collected and the concentration of methylprednisolone incorporated 
in the formulations was analyzed separately using Shimadzu UV 





Sa= Total amount of drug in the system, Sb= Amount of drug in the 
supernatant after centrifugation. 
FT-IR studies for optimized formulation 
Cross-linking reaction between the phosphoric group of 
tripolyphosphate (TPP) and an amino group of chitosan was 
analyzed to confirm using Perkin Elmer Spotlight 200i FT-IR. 
Homogeneously dried formulation was used to prepare KBr pellet, 
where the powder was compressed under vacuum using a round flat 
face punch. Samples were scanned from about 4000-400 cm-1 
Drug release was performed in vitro using the dialysis bag method. 
Dialysis bags were soaked in deionized water overnight prior to the 
experiment. Nanoparticles dispersion of 2 ml is placed in the dialysis 
bag of 2000 Da and fixed two ends with the help of clamps. The bags 
were transferred into 250 ml phosphate buffer pH 7.4 and in 
simulated colonic fluid (Fed and Fasted state) kept at 35±0.5 °C for 
the determination of drug release. Samples were withdrawn at a 
specified time intervals for about 24 H. At the predetermined time 
intervals 1 ml of sample was withdrawn by adding the fresh 
buffer/fresh simulated colonic fluid. The samples were analyzed 
using UV spectrophotometry at 242 nm. All the measurements were 
done in a triplicate [23]. By using various kinetic models mechanism 
of drug release was noted based on R
[21]. 
Powder X-ray diffraction (PXRD) 
Information regarding crystal lattice arrangements and the degree 
of crystallinity of optimized MCSNPs was analyzed using PXRD. To 
analyze the physical state, PXRD spectra of dried nanoparticles were 
recorded at room temperature using Arex X-ray diffractometer with 
a voltage of 3Kv, 5Ma current with a scanning speed of 40/min. 
Samples were scanned from 0 to 600 (2ϴ) range with a step interval 
of 0.1 seconds [22]. 
In vitro drug release 
2
RESULTS AND DISCUSSION 
 and ‘n’ value. 
Statistical analysis (Box-behnken design) 
The results of Box-Behnken design were analyzed and the utility of 
this statistical design resulted in providing considerable information 
to optimize the formulation. All the responses were fitted to a 
quadratic model and compatibility of the model was verified by 
ANOVA, lack of fit and co-efficient of determination (R2
Blank chitosan nanoparticles were formulated to optimize the 
concentration of chitosan, TPP and acetic acid based on the 
dependent variables like particle size, zeta potential and 
polydispersity index (PDI). Results for the responses were shown in 
table 5. With an increase in the concentration of chitosan and TPP, 
particle size and zeta potential were increased and vice versa. PDI 
increased linearly with the increase in the concentration of acetic 
acid was in acceptance according to the literature [26-28]. P-Values 
for the responses y
). To optimize 
the responses, every response should be interconnected with each 
other and a most supportive zone must be required for every 
response to exclude bias. Desirability function was supported by 
much literature to optimize the multiple responses [24, 25]. 
1, y2, y3 was found to be 0.002, 0.001, 0.034. 
Hence, the quadratic model is best fitted for all the responses with 
*P<0.05. Table 6 shows a summary of the regression analysis of all 
the responses. Polynomial equations 1, 2, 3 for Y1, Y2, Y3 explains the 
significant model terms with *P<0.05. The variables with negative 
values represent negative effects on responses. Based on the 
desirability function, interaction effects between two factors and 
confirmation location was predicted using 2D contour and 3D 
response surface graphs shown in table 7 and fig. 1-4. Among the 
responses, Y1 and Y3 were set in minimize, whereas Y2 in range. 
Confirmation location for the optimized formulation was achieved at 
A = 3.30 mg/ml, B = 1.36 mg/ml, C = 0.2 mg/ml with Y1 = 238.64 
nm, Y2 = 30 mV and Y3 
Formulation code 
= 0.175. Observed values for the 
confirmation location were close to the predicted values showing 
that Box-Behnken Design can be considered being the best tool in 
formulating methylprednisolone chitosan nanoparticles. 
 
Table 5: Optimization of blank chitosan-based nanoparticles using ionic gelation technique: (Formulation–blank CSNPs) n=13 
Response-1 (Y1 Response-2 (Y) 
particle size (nm) 
2 Response-3 (Y) 
zeta potential (mV) 
3) 
PDI 
CNI-1 359±6.31 59.19±0.69 0.231±0.003 
CNI-2 196±4.34 21.13±1.02 0.186±0.002 
CNI-3 245±6.45 33.43±0.53 0.193±0.001 
CNI-4 180±7.32 19.32±0.49 0.173±0.004 
CNI-5 183±8.12 20.11±1.16 0.197±0.002 
CNI-6 293±9.11 39.61±0.59 0.216±0.004 
CNI-7 289±8.13 35.51±0.89 0.177±0.003 
CNI-8 329±6.21 49.12±1.32 0.217±0.002 
CNI-9 231±6.34 31.21±1.11 0.232±0.003 
CNI-10 219±7.22 26.17±1.34 0.189±0.003 
CNI-11 392±3.45. 62.21±0.67 0.206±0.002 
CNI-12 347±5.45 52.31±0.78 0.181±0.006 
CNI-13 173±6.34 16.12±0.65 0.192±0.003 
*Data from each response is presented in mean±SD (n=3) 
 
Table 6: Summary of regression analysis of the responses (CSNPs) 
Quadratic model R Adjusted R2 SD 2 Adequate Precision p-value 
Response-1 particle size (nm) 0.99 0.98 9.57 27.19 0.0020 
Response-2 zeta potential (mV) 0.99 0.99 0.51 98.00 0.0001 
Response-3 PDI 0.99 0.97 0.0028 24.36 0.0342 
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Polynomial equations with intercept and coded factors (CSNPs) 
Y1 = +245 + 86.87A(∗ P < 0.05) + 27.25B(∗ P < 0.05) + 3.87C(P > 0.05) + 10AB(P > 0.05) + 2.25AC(P > 0.05) − 2BC(P > 0.05) + 18.37A2(∗ P < 0.05)
+ 9.12B2(P > 0.05) + 3.87C2(P > 0.05) (1)  
Y2 = +33.43 + 18.26A(∗ P < 0.05) + 4.48B(∗ P < 0.05) + 2.10C(∗ P < 0.05) + 2.02AB(∗ P < 0.05) + 1.52AC(∗ P < 0.05) − 0.23BC(P > 0.05)
+ 4.16A2(∗ P < 0.05) − 0.44B2(P > 0.05) + 0.14C2(P > 0.05) (2)  
Y3 = +0.19 + 0.01A(∗ P < 0.05) − 0.00B(∗ P < 0.05) + 0.01C(∗ P < 0.05) − 0.00AB(P > 0.05) + 0.00AC(∗ P < 0.05) − 0.00BC(P > 0.05)
− 0.00A2(P > 0.05) + 0.00B2(∗ P < 0.05) + 0.00C2(P > 0.05) (3)  
 
 
Fig. 1: 2D Response surface contour plots showing desirability between factors and responses (CSNPs) 
 
 
Fig. 2: 3D Response surface plots showing factors with particle size (CSNPs) 
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Fig. 3: 3D Response surface plots showing factors with zeta potential (CSNPs) 
 
 
Fig. 4: 3D Response surface plots showing factors with PDI (Polydispersity index) (CSNPs) 
 
 
Fig. 5: Average particle size of optimized formulation (blank CSNPs) 
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Table 7: Comparison of predicted and observed values of blank CSNPs 
Confirmation location Chitosan (A) TPP (B) Acetic acid (C) 
3.30 1.36 0.2 
Response Predicted value Observed value (n=3) Residuals *Bias % 
Particle size (nm) 238.64 233±13.3 -5.64 2.42 
Zeta potential (mV) 30 32.01±3.11 2.1 -6.27 
PDI 0.175 0.171±0.004 -0.004 2.33 
∗ Bias % = ((Predicted value − Observed value) ∗ 100 Observed value⁄  *Data from each response for the observed values is presented in mean±SD (n=3) 
 
MCSNPs were formulated to optimize the concentration of 
methylprednisolone, stirring speed and temperature based on the 
dependent variables like particle size, zeta potential and encapsulation 
efficiency. Table 8 shows the results for responses. P-Values for the 
responses y1, y2, y3 was found to be 0.0084, 0.0143, and 0.0171. Hence, 
the quadratic model is best fitted for all the responses with *P<0.05. 
Table 9 shows a summary of the regression analysis of all the responses. 
Based on the desirability function, interaction effects between two 
factors and confirmation location was predicted using 2D contour and 
3D response surface graphs shown in table 10 and fig. 6–10. Among the 
responses, Y2 and Y3 were set in maximize, whereas Y1 in the 
minimized. Confirmation location for the optimized formulation was 
achieved at A = 0.72 mg/ml, B = 531.24 rpm, C = 27.90 °C with Y1 = 
251.08 nm, Y2 = 46.43 mV and Y3 
Formulation code 
= 80.89% (Desirability–0.86). An 
overlay contour plot shown in fig. 10 explains the most supportive zone 
for all the responses. Observed values were found to be very close to the 
predicted values of confirmation location indicating the best 
optimization results using Box-Behnken Design. 
  
Table 8: Optimization of methylprednisolone chitosan-based nanoparticles using ionic gelation technique: (Formulation–
methylprednisolone CSNPs) n=13 
Response-1 (Y1 Response-2 (Y) particle size (nm) 2 Response-3 (Y) zeta potential (mV) 3)% EE 
MCSNP-1 291.02±7.21 43.96±3.54 77.19±2.45 
MCSNP-2 260.13±5.64 46.43±4.32 81.12±3.11 
MCSNP-3 284.22±5.78 38.17±2.11 80.46±2.13 
MCSNP-4 219.04±6.32 31.89±1.32 63.92±2.54 
MCSNP-5 249.11±3.42 37.14±2.44 76.14±1.32 
MCSNP-6 245.21±4.56 30.17±3.15 61.41±2.08 
MCSNP-7 303.17±6.32 22.19±3.54 69.46±3.11 
MCSNP-8 312.16±2.43 36.58±2.67 70.31±2.94 
MCSNP-9 229.13±5.67 34.16±2.89 57.43±2.31 
MCSNP-10 264.11±7.54 22.13±3.41 70.63±2.41 
MCSNP-11 224.21±8.32 20.11±1.83 53.17±1.36 
MCSNP-12 267.14±3.56 41.12±1.62 68.34±2.47 
MCSNP-13 279.21±4.32 24.49±2.43 64.92±2.63 
*Data from each response is presented in mean±SD (n=3) 
 
 
Fig. 6: 2D Response surface contour plots showing desirability between factors and responses (Methylprednisolone CSNPs) 
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Table 9: Summary of regression analysis of the responses (methylprednisolone CSNPs) 
Quadratic model R Adjusted R2 SD 2 Adequate Precision p-value 
Response-1 particle size (nm) 0.98 0.57 6.16 16.67 0.0084 
Response-2 zeta potential (mV) 0.98 0.93 2.15 13.71 0.0143 
Response-3 % EE 0.98 0.93 2.26 13.62 0.0171 
 
 
Fig. 7: 3D Response surface plots showing factors with particle size (MCSNPs) 
 
 
Fig. 8: 3D Response surface plots showing factors with zeta potential (MCSNPs) 
 
Table 10: Comparison of predicted and observed values of MCSNPs 
Confirmation location Methylprednisolone (mg/ml) Stirring speed (RPM) Temperature ( °C) 
0.72 531.24 27.90 
Response Predicted value Observed value (n=3) Residuals *Bias % 
Particle size (nm) 251.08 243±2.33 -8.08 3.32 
Zeta potential (mV) 46.43 42.34±1.23 -4.09 9.65 
% EE 80.89 79.3±7.2 -1.59 2.00 
∗ Bias % = ((Predicted value − Observed value) ∗ 100 Observed value⁄  *Data from each response for the observed values is presented in mean±SD 
(n=3). 
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Fig. 9: 3D Response surface plots showing factors with encapsulation efficiency (MCSNPs) 
 
 
Fig. 10: Overlay contour plot for methylprednisolone CSNPs (MCSNPs) 
 
 
Fig. 11: Average particle size of optimized MCSNPs 
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Particle size 
There is an increase in particle size with increasing the 
concentration of methylprednisolone. Particle size 
From equation 5, the independent variables like A, B, C, A
was found to be 
increased with an increase in stirring speed up to 600 rpm and 
decreased thereafter which maybe because of the prevalence of high 
shearing rates that destroys the repulsive forces leading to 
aggregation [29, 30]. Particle size decreased linearly from 
312.16±2.43 to 219.04±6.32 with an increase in temperature which 
is shown in 3D response surface graphs (fig. 7). Polynomial equation 
with an intercept and coded factors is as follows- 
Y1 = +260.13 + 34.12A(∗ P < 0.05) + 4.28B(P > 0.05)
− 10.90C(∗ P < 0.05) + 4.26AB(P > 0.05)
− 0.44AC(P > 0.05) + 0.73𝐵𝐵𝐵𝐵(P > 0.05)
+ 1.00A2(P > 0.05) + 0.74B2(P > 0.05)
+ 4.01C2(P > 0.05) (4)  
From the equation, independent variables like A and C were 
significant as the p-value is less than 0.05. The observed value of 
particle size for the confirmation location was found to be 243±2.33 
and the results were given in table 10 and fig. 11. 
% Encapsulation efficiency (EE) 
% EE of all the MCSNPs ranged from 53.17±1.36 to 81.12±3.11%. 
Polynomial equation with an intercept and coded factors is as follows- 
Y3 = +81.12 + 7.68A(∗ P < 0.05) − 2.61B(∗ P < 0.05)
+ 3.27C(∗ P < 0.05) − 0.86AB(P > 0.05)
+ 0.91AC(P > 0.05) − 0.52BC(P > 0.05)
− 8.89A2(∗ P < 0.05) − 7.91B2(∗ P < 0.05)




was significant as the p-value is less than 0.05. Encapsulation 
efficiency was found to be increased up to 0.75 mg/ml concentration 
of methylprednisolone and decreased thereafter. Further, the 
increase in methylprednisolone concentration lead to a decrease in 
% EE, which may be because of the precipitation of chitosan 
molecules in the dispersion. % EE was found to be increased up to 
600 rpm and decreased thereafter which may be due to the 
prevalence of high shearing rates that destroys the repulsive forces 
leading to aggregation [29, 30]. These results were shown in 3D 
response surface graph-fig. 9. Observed % EE of the optimized batch 
was found to be 79.3±7.2 with particle size 243±2.33. 
Zeta potential of all MCSNPs ranged from 21.31±3.36 to 43.21±1.79 
mV. Polynomial equation with intercept and coded factors is as 
follows- 
Y2 = +46.43 + 3.07A(∗ P < 0.05) − 8.43B(∗ P < 0.05)
− 0.37C(P > 0.05) − 1.93AB(P > 0.05)
− 0.03AC(P > 0.05) + 0.40BC(P > 0.05)
− 6.67A2(∗ P < 0.05) − 9.65B2(∗ P < 0.05)
− 5.5C2(∗ P < 0.05) (6)  
From equation 6, independent variables like A, B, A2, B2 and C2
Morphology 
 were 
significant as the p-value is less than 0.05. Zeta potential was mainly 
affected by stirring speed and temperature. At higher speeds and 
temperature a decrease in the viscosity of chitosan leads to 
structural instability decreasing zeta potential [31]. Observed value 
of zeta potential for the confirmation location was found to be 
+43.34±1.23. This positive surface charge leads to interaction with 
mucin and has the characteristics of mucoadhesion [32]. 
Scanning electron microscopy reveals that there is an increase in the 
particle size of MCSNPs when compared to CSNPs. From the 
micrographs (fig. 12), it was evident that particles were rough in 
texture with the nearly spherical shape. 
 
 
A      B 
Fig. 12: SEM photographs of A) Optimized CSNPs, B) Optimized MCSNPs (mean±SEM), n=3 
 
 
Fig. 13: FT-IR of methylprednisolone (pure drug), optimized blank chitosan nanoparticles (CSNPS), optimized methylprednisolone 
nanoparticles (MCSNPS) 
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Differential scanning calorimetry 
Broad endothermic peak was observed at 236.1 °C for 
methylprednisolone corresponding to its melting point shown in fig. 
14. CSNPs experienced two endothermic peaks at 56.8 °C and 330.2 
°C, in relation to evaporation of water and degradation of chitosan 
respectively [36, 37]. Endothermic peak of methylprednisolone was 
shifted from 236.1 °C to 280.3 °C in MCSNPs indicating superior 
thermal stability of methylprednisolone. 
X-ray diffraction 
Powdered X-ray diffraction patterns for the pure methylprednisolone 
and optimized MCSNPs were shown in fig. 15. Pure 
methylprednisolone showed larger Lin (counts) when compared to 
optimized MCSNPs. Fewer intensities of methylprednisolone in 
MCSNPs indicates that the drug is in disordered crystalline or in 
amorphous form. This study indicates the improvement of solubility of 
methylprednisolone in MCSNPs [38]. 
 
 




Fig. 15: PXRD of methylprednisolone and optimized methylprednisolone nanoparticles (MCSNPS) 
 
In vitro drug release studies 
Cumulative drug release for optimized MCSNPs was conducted for 
24 h in phosphate buffer and simulated colonic fluids (SCF) as 
shown in table 11 and fig. 16. Cumulative drug release of 
methylprednisolone CSNPs in phosphate buffer pH 7.4, SCF pH 7, 
SCF pH 6 (Fed state), SCF pH 7.8 (Fasted state) was found to be 
99.97±3.02, 99.07±3.51, 96.63±1.53 and 98.63±2.52% respectively.  
In SCF pH 6 (Fed state) over 95% of the drug was released within 
11 H, which may be due to the solubility of chitosan in acidic and 
slightly acidic pH [39]. From the results, it was found that over 
99% of the drug was released in 24 h in phosphate buffer pH 7.4 
and SCF pH 7 and SCF pH 7.8 (Fasted state) which was found to be 
the best when compared to the drug release in other SCF pH 6 
(Fed state). 
Results were fitted with various kinetic models as shown in table 12. 
Korsemeyer-peppas was found to be the best-fitted model with a 
mechanism of drug release as non-fickian diffusion with n value 
ranging from 0.64-0.82. 
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Table 11: In vitro drug release studies of methylprednisolone CSNPs 
Time (H) % Drug release 
(phosphate buffer pH 7.4) 
% Drug release simulated 
colonic fluid-pH 7 
% Drug release simulated 
colonic fluid (Fed State)-pH 6 
% Drug release simulated colonic 
fluid (Fasted State)-pH 7.8 
1 11.67±5.01 13.93±0.90 14.73±1.53 10.63±2.52 
2 25.13±2.84 23.17±3.51 28.17±1.69 13.77±2.04 
3 27.93±2.81 27.07±2.61 34.83±0.68 17.13±2.73 
4 32.43±1.82 34.80±2.16 38.13±1.53 23.10±3.73 
5 35.93±1.62 37.80±2.76 42.80±3.50 34.00±3.77 
6 43.33±1.59 42.17±3.51 59.93±1.58 38.97±2.63 
7 47.73±1.75 44.73±2.01 65.47±3.44 46.53±1.57 
8 51.03±2.73 52.47±3.66 76.07±1.37 51.53±2.52 
9 58.23±2.81 54.60±2.43 79.63±1.53 58.23±1.66 
10 63.13±2.94 63.73±4.98 86.70±2.82 62.73±2.52 
11 66.73±2.63 65.37±3.51 96.63±1.53 68.10±2.71 
12 72.13±2.11 78.07±2.61 - 74.93±2.52 
16 84.13±2.72 86.40±4.46 - 88.63±2.53 
24 99.97±3.02 99.07±3.51 - 98.63±2.52 
(*Data from each profile is presented in mean±SD (n=3)) 
 
Table 12: Drug release kinetics of optimized MCSNPs 
MCSNPs Zero-order (R2 First-order (R) 2 Higuchi (R) 2 Korsmeyer peppas ) 
(R2 (n) ) 
MCSNPs-PBS (pH 7.4) 0.93 0.73 0.98 0.98 0.67 
MCSNPs-SCF FED (pH 6) 0.98 0.83 0.94 0.98 0.76 
MCSNPs-SCF FASTED (pH 7.8) 0.92 0.93 0.94 0.97 0.82 
MCSNPs-SCF (pH 7) 0.92 0.89 0.97 0.99 0.64 
(*Data from each parameter is presented in replication (n=3)) 
 
 
Fig. 16: Cumulative % drug release of optimized methylprednisolone nanoparticles (MCSNPS) in various fluids (SCF-simulated colonic 
fluid, PBS–phosphate buffer), (*Data from each profile is presented in mean±SD (n=3)) 
 
CONCLUSION 
Methylprednisolone chitosan-based nanoparticles were successfully 
optimized using Design-Expert software by applying BBD and RSM. 
Amorphous nature and thermal stability of MCSNPs were confirmed 
using PXRD and DSC. Encapsulation efficiency of MCSNPs was nearly 
80% and the formation of hydrogen bonds between the chitosan and 
methylprednisolone was confirmed using FT-IR. The prepared 
nanostructures showed an extended-release of MCSNPs in simulated 
colonic fluids with improved bioavailability. Though the results 
seem to be successful in SCF in vitro, further research should be 
carried out to coat MCSNPs using pH-sensitive polymers to decrease 
the solubility of chitosan in upper GIT. 
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